Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances Wages, Salaries and Other

Bioregenx (BRGX) Short-Term Debt repayments (2022 - 2023)

Bioregenx has reported Short-Term Debt repayments over the past 2 years, most recently at $10981.0 for Q4 2023.